Advances in Cardiac Treatment
This story was originally published in the Winter 2022 edition of Providence St. Joseph Health Matters.
In this article:
Providence St. Joseph cardiologists are having success finding and treating heretofore sneaky heart condition, cardiac amyloidosis (CA).
Technicians have found a specialized type of imaging, originally developed as a bone scan, to be very effective at detecting CA.
Interventional cardiologist, Dr. Brian Kolski and the team take a multidisciplinary approach when treating patients with potential indicators of CA.
Providence St. Joseph is one of the few places actively screening for CA.
Cardiac amyloidosis (CA) might be a singularly unfamiliar term unless you are one of the 100,000 in the United States who have been diagnosed with it. Still, it’s a confounding condition and one that specialists at Providence St. Joseph Hospital have been studying with great success. Brian Kolski, MD, an interventional cardiologist, and director of the structural heart program at Providence St. Joseph, is one of those specialists. CA is a type of cardiovascular disease in which an overproduction and dumping of abnormal amyloid protein—a misfolded and insoluble protein—is deposited in the heart’s valves, atria, or ventricles. The deposits can cause the thickening of these sections and decrease the heart’s function. “Basically,” says Dr. Kolski, “it causes pump failure.” This disease has been widely misdiagnosed and is often not properly diagnosed at all until an autopsy occurs. “We started studying CA out of necessity,” Dr. Kolski says. “People were experiencing heart failure and we didn’t have the proper tools. We began clinical trials to discover ways to detect and treat it, and now have actual therapies that can help arrest it and prevent it from getting worse.”
Dr. Kolski suspects that the current estimate of 1 in 6,000 heart patients having cardiac amyloidosis might be on the low side: “As we start to understand and are better at diagnosing, the number gets higher.” He says there are two kinds of CA: a hereditary or genetic type and a “wild” mutation.
Screening and attention are key
“There are indicators, especially in elderly patients, that point to the need for a nuclear imaging scan, “Dr. Kolski explains. “Those indicators include congestive heart failure, neuropathy and weakness in the legs, and carpal tunnel syndrome.” Technicians have found that a specialized type of imaging called 99mTc-pyrophosphate (PYP), which was originally developed as a bone scan, is very effective at finding cardiac amyloidosis. Providence St. Joseph is one of the few places actively screening for CA; the PYP imaging is an important test not many others are offering, says Dr. Kolski. “Once we do the screening, we plug patients into a clinical trial that uses a combination of drugs; we also pair the treatment with genetic screening and the patient with a genetic counselor.” Drugs can treat both the hereditary and wild types of the disease. And Dr. Kolski’s team takes a multidisciplinary approach, which includes a hematologist and a neurologist and possibly “access to a liver transplant because that’s where the proteins are being produced.” Dr. Kolski has come to the conclusion that patients who present with heart failure, but normal pumping should be evaluated for a PYP scan, “especially when they have neurological conditions such as carpal tunnel and muscle weakness.”
Find a doctor
Download the Providence App
We’re with you, wherever you are. Make Providence’s app your personalized connection to your health. Schedule appointments, conduct virtual visits, message your doctor, view your health records, and more. Learn more and download the app.
This information is not intended as a substitute for professional medical care. Always follow your health care professional's instructions.